» Articles » PMID: 15146556

BRCA1 Mutations in South African Breast And/or Ovarian Cancer Families: Evidence of a Novel Founder Mutation in Afrikaner Families

Overview
Journal Int J Cancer
Specialty Oncology
Date 2004 May 18
PMID 15146556
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Germ-line mutations within BRCA1 are responsible for different proportions of inherited susceptibility to breast/ovarian cancer, and the spectrum of mutations within this gene is often unique to certain populations. At this time, there have been no reports regarding the role of BRCA1 in South African breast and/or ovarian cancer families. We therefore screened 90 South African breast/ovarian cancer families for BRCA1 mutations by means of PCR-based mutation detection assays. Eighteen families (20%) were identified with BRCA1 disease-causing mutations. Four Ashkenazi Jewish families were identified with the 185delAG mutation, whereas 2 Afrikaner and 1 Ashkenazi Jewish family were found to harbor the 5382insC mutation. Five of the families (5.56%), all of whom are Afrikaners, were found to carry the novel E881X mutation. Genotype analyses show that these patients share a common ancestor. Genealogic studies have identified 3 possible founding couples for this mutation, all of whom arrived in the Cape from France in the late 1600s. Of the remaining mutations detected, 3 have not been reported previously and include the S451X, 1493delC (detected twice) and 4957insC mutations.

Citing Articles

Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients.

van der Merwe N, Buccimazza I, Rossouw B, Araujo M, Ntaita K, Schoeman M Breast Cancer Res Treat. 2024; 207(2):331-342.

PMID: 38814507 PMC: 11297091. DOI: 10.1007/s10549-024-07362-2.


Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations.

Iwai Y, Toumbou K, Zuze T, Morgan J, Simwinga L, Wright S JCO Glob Oncol. 2023; 9:e2300154.

PMID: 37944088 PMC: 10645409. DOI: 10.1200/GO.23.00154.


Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector.

van der Merwe N, Ntaita K, Stofberg H, Combrink H, Oosthuizen J, Kotze M Front Oncol. 2022; 12:938561.

PMID: 36568162 PMC: 9768488. DOI: 10.3389/fonc.2022.938561.


Prevalence of Clinically Relevant Germline Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience.

van der Merwe N, Combrink H, Ntaita K, Oosthuizen J Front Genet. 2022; 13:834265.

PMID: 35464868 PMC: 9024354. DOI: 10.3389/fgene.2022.834265.


Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

ElBiad O, Laraqui A, El Boukhrissi F, Mounjid C, Lamsisi M, Bajjou T BMC Cancer. 2022; 22(1):208.

PMID: 35216584 PMC: 8876448. DOI: 10.1186/s12885-022-09181-4.